SAHPRA Halts New Cannabis Section 21 Approvals
The regulator's July 2026 decision has left patients with medical needs without legal access to prescribed cannabis treatments.
Updated on Nov. 10, 2026 in Diseases

The South African Health Products Regulatory Authority (SAHPRA) halted new Section 21 cannabis approvals in July 2026 and withdrew approvals for some patients. The decision followed reported concerns over alleged abuse of the Section 21 system by unscrupulous cannabis operators.
Why it matters
Patients with drug-resistant epilepsy, including children, have lost legal access to prescribed cannabis treatments under the Section 21 framework. Families are now adjusting doses of existing medication while awaiting approvals that have not been granted.
The evidence is a regulatory decision with individual patient accounts rather than population statistics. The number of approvals withdrawn and the number of patients affected were not reported, and the timeline for resuming approvals is unknown.
The players
South African Health Products Regulatory Authority (SAHPRA)
SAHPRA is South Africa's national regulator responsible for approving medicines and health products, including the Section 21 pathway for unregistered medicines.
The details
SAHPRA halted new Section 21 approvals in July and withdrew existing approvals for some patients. Ursula reduced her son's AKOS T100 Nova dose because Section 21 has not approved the product, while Matt has had seizures for 18 years since age 12 and a half.
Timeline
July 2026: SAHPRA halts new Section 21 cannabis approvals.
10 November 2026: Article published on patient access concerns.
Health Landscape
The halt applies to the Section 21 provision of the Medicines and Related Substances Act, which allows individual unregistered medicines to be approved for specific patients. Tightening its use shifts access for patients who depend on it for treatments not yet registered in South Africa.
Patients on Section 21 cannabis treatments may need to adjust doses or seek alternatives while approvals are on hold. Families should confirm their current approval status with their prescribing doctor before changing any medication.
The takeaway
Patients relying on Section 21 approvals should keep their prescribing doctor informed of any dose changes or access problems. Tracking official SAHPRA communications can help families plan around the pause.
Further reading
For related context on respiratory and chronic conditions, see the Asthma section.
Source note: This article includes information reported by EWN Traffic.






